BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients

BRAF inhibitors (BRAFi) improve progression-free survival and overall survival in patients with advanced melanoma (1,2), with 3 to 6% of patients experiencing complete remission (CR)(1,3). Nevertheless, this efficacy comes at a cost with 90% of patients experiencing at least one adverse event and 45% grade 3 or 4 adverse events (4). Management of long-term responders is not yet well delineated: safety argues for treatment continuation, because evolution after discontinuation is unknown. This article is protected by copyright. All rights reserved.